跳至主要内容
临床试验/NCT00394186
NCT00394186已完成2 期

A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the Beta-3-Adrenergic Receptor Agonist Solabegron in Subjects With Irritable Bowel Syndrome

GlaxoSmithKline20 个研究点 分布在 3 个国家目标入组 100 人开始时间: 2006年8月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
100
试验地点
20
主要终点
completion of questionnaires by the subject, determining the average adequate relief rate

研究概览

简要总结

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • - Diagnosis of IBS which meets the Rome II criteria, screening pain score to be > 1.5 (0= no pain, 4 = very severe pain)

排除标准

  • Subjects not meeting the Rome II criteria for the diagnosis of IBS
  • Subjects with no stool for 7 days during the screen

结局指标

主要结局

completion of questionnaires by the subject, determining the average adequate relief rate

时间窗: during the last 4 weeks of the treatment periods (weeks 3 to 6 in period 1 and weeks 15-18 in period 2)

次要结局

  • clinical lab tests(Weeks 1, 6, 12, 18, 24)
  • Blood levels of GW427353(Week 1, 13)
  • Questionnaire(Weeks 1, 6, 12, 18, 24)
  • ECG, vital signs, adverse events(each visit)

研究者

申办方类型
Industry

研究点 (20)

Loading locations...

相似试验